Grants

W03-016: Effect of platelet-derived growth factor receptor inhibition on vaccine-associated sarcoma radiosensitivity

New treatments for vaccine-associated cancer are desperately needed. Investigations have recently begun to evaluate the role of radiation therapy and chemotherapy for these cancers with encouraging results, yet many still reoccur. Recently a new drug (ST1571) that targets a specific growth factor of these cancer cells (platelet-derived growth factor – PDGF) has been shown to increase the benefits of chemotherapy. This new study hopes to prove this drug (ST1571) will also increase the efficacy and benefits of radiotherapy as well.

Grant ID: W03-016

Status: Active

Year Funded: 2003

Amount awarded: $14,579

Investigator: Douglas H. Thamm, VMD, DACVIM (Oncology), Michelle M. Turek, DVM, DACVIM (Oncology), David M. Vail, DVM, MS, DACVIM (Oncology), Ilene D. Kurzman, MS, EdD, Lisa J. Forrest, VMD, DACVR (Radiology/Radiation Oncology); University of Wisconsin – Madison